← Back to Search

Procedure

Cryoanalgesia for Post-VATS Pain (CRYO-VATS Trial)

N/A
Recruiting
Led By Alex Moore, MD
Research Sponsored by Centre hospitalier de l'Université de Montréal (CHUM)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 hour, 6 hours, 12 hours, 18 hours, 24 hours, 48 hours and 7 days
Awards & highlights

CRYO-VATS Trial Summary

This trial aims to show the effectiveness of a cryotherapy technique to provide pain relief after lung surgery.

Who is the study for?
This trial is for patients scheduled for elective lung cancer surgery (like removing a part of the lung) using VATS, with an ASA score indicating they are fit for anesthesia and surgery. It's not suitable for those outside this group.Check my eligibility
What is being tested?
The study tests if adding intercostal cryoanalgesia to a single paravertebral block can better manage pain after VATS lung resection compared to just the block alone.See study design
What are the potential side effects?
Cryoanalgesia may cause localized numbness, skin changes, or nerve damage. The paravertebral block could lead to discomfort at injection site, bleeding, infection, or rarely breathing difficulties.

CRYO-VATS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 hour, 6 hours, 12 hours, 18 hours, 24 hours, 48 hours and 7 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 hour, 6 hours, 12 hours, 18 hours, 24 hours, 48 hours and 7 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
Acute thoracic pain at rest
Acute thoracic pain during cough
Evaluation of sedation related to opioid consumption
+7 more

CRYO-VATS Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Intercostal cryoanalgesia AND single-injection paravertebral blockExperimental Treatment1 Intervention
Videothoracoscopic-guided single-injection paravertebral block at T5 with 0.4 mL/kg of Bupivacaine 0.5% with adrenalin 5 mcg/mL (maximum 40 mL) at the beginning of surgery Cryoanalgesia 5 cm lateral to the neuraxial, on the inferior costal border, CO2 at (-)50C to (-)70C for 2 minutes, repeated on 7 costal levels (T3-T9), after the lung resection and before chest closure.
Group II: Single-injection paravertebral blockActive Control1 Intervention
-Videothoracoscopic-guided single-injection paravertebral block at T5 with 0.4 mL/kg of Bupivacaine 0.5% with adrenalin 5 mcg/mL (maximum 40 mL) at the beginning of surgery

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments in thoracic surgery include intercostal cryoanalgesia, paravertebral blocks, and systemic analgesics. Intercostal cryoanalgesia works by freezing the intercostal nerves, leading to prolonged pain relief by causing localized nerve damage that temporarily interrupts pain signal transmission. Paravertebral blocks involve injecting anesthetics near the spinal nerves to block pain in the thoracic region. Systemic analgesics, such as opioids and NSAIDs, work by reducing pain perception and inflammation throughout the body. These treatments are crucial for thoracic surgery patients as they significantly reduce postoperative pain, enhance recovery, and improve overall patient outcomes.
Bronchoscopic cryotherapy for advanced bronchial carcinoma.Cryotherapy for advanced carcinoma of the trachea and bronchi.Treatment of Pulmonary Carcinoid Tumors With Bronchoscopic Cryotherapy: A 28-Year Single-center Experience.

Find a Location

Who is running the clinical trial?

Centre hospitalier de l'Université de Montréal (CHUM)Lead Sponsor
370 Previous Clinical Trials
129,789 Total Patients Enrolled
Alex Moore, MDPrincipal InvestigatorCentre Hospitalier de l'Universite de Montreal
1 Previous Clinical Trials
80 Total Patients Enrolled
~33 spots leftby Nov 2024